about
Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systemsPhase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsAdverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancerManagement of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancerSafety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort studyPhysician Experience and Attitudes Toward Addressing the Cost of Cancer Care.Decision making and quality of life in the treatment of cancer: a review.Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.Standards for palliative care delivery in oncology settings.Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.Consensus-based standards for best supportive care in clinical trials in advanced cancer.Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research.Best supportive care in clinical trials: review of the inconsistency in control arm design.Discussing Health Care Expenses in the Oncology Clinic: Analysis of Cost Conversations in Outpatient Encounters.The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.The utility of cost discussions between patients with cancer and oncologists.Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.Financial Toxicity of Cancer Care: It's Time to Intervene.The need for a re-evaluation of best supportive care studies reported to date.Does comparative effectiveness research promote rationing of cancer care?Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress.Price of Cancer Care and Its Tax on Quality of Life.Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act.Establishing a regional, multisite database for quality improvement and service planning in community-based palliative care and hospice.In ReplyPlace of death for patients with cancer in the United States, 1999 through 2015: racial, age, and geographic disparitiesLinks Between Communication and Relationship Satisfaction Among Patients With Cancer and Their Spouses: Results of a Fourteen-Day Smartphone-Based Ecological Momentary Assessment StudyHealth-Related Quality of Life: The Impact on Morbidity and Mortality.Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care.Financial burden among older, long-term cancer survivors: Results from the LILAC studyA phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerFinancial Toxicity and Equitable Access to Clinical TrialsPerspectives on the Costs of Cancer Care: A Survey of the American Society of Breast SurgeonsFinancial Costs and Burden Related to Decisions for Breast Cancer Surgery
P50
Q33387054-6E4F5938-71BD-4EAD-9DC1-21010F324A9AQ33402040-BD7C4523-682C-4BD1-9765-4AC52619102DQ33628784-EACD96B7-9AC3-4AF8-8DE7-6CE4B72C748BQ33854239-EB70B38C-9EBE-4AEB-AA1F-1CBCA2DEBCEEQ33861319-F2CB327E-DCD4-4CE7-8D50-4DE669887B4FQ33921891-BA5BDB4B-8DA2-464A-A836-459F54B11EFEQ33994024-2C33BDE3-B0B3-41AF-B1B9-F8BDB2D95EA0Q35584707-D62F2366-1280-4B07-932A-5D8537D8BD04Q36200626-DCB7FF1F-46F1-4965-92F2-721494980BA6Q36542468-5B39130E-C600-4BAB-8FC3-F2F9FCA70E76Q37125060-3F782EA7-C5B4-4BEC-9A9F-44614A65D305Q37273366-FDD94C71-08B2-47B9-96DE-3D55032F793FQ37767815-11E1E48A-96E6-40FF-B4A6-3736967DD08FQ37796540-61738030-209C-44A7-B81C-C83395BBE989Q37974101-3CB93189-F45C-4511-B2E3-AE6683FF592EQ37980958-BEEA1943-5DA4-46DF-BF48-F93BFAF609C9Q37996694-E941FB5F-2FAF-40C7-9FBE-52724C3E660BQ38525870-FE6AD52C-09B9-460D-BA19-4D725E1A774BQ38611581-3EB6052D-325E-4E9D-A475-E68CB6CD19A8Q38874589-4C41A2CA-7E15-4F5E-9094-E00409426146Q38989596-C2B85B8F-4E55-4024-BB6E-396F640FCAACQ40262545-9A519065-275E-4FF3-8E96-B09B94A4A1F3Q40421115-795FFA27-6FFB-4D76-8658-301160EDC54DQ41058870-A87E2B28-18BD-4F40-88B1-60B2B6317AFFQ42653277-A8C38B24-D2F3-438B-A773-20C0FED9DED3Q46842669-48FA3A55-7A45-49C4-9341-6EEB6351375AQ48078636-EA3283D1-9FE5-4F2F-B979-574656C4C4F0Q49580097-E4E87095-1181-44DD-BD65-E4C3A775D3C8Q50048931-8458A484-307A-4E8C-B795-20AC1D9A34CFQ50133886-AF4249CA-8533-473B-9FCB-9734C8CF3EEDQ57360806-8D47909A-BF22-42D4-9E84-F600F0249D5FQ57806332-AD27B47E-CF47-434F-AE28-B3A793B00CB3Q58576368-F874D472-D3B3-4A67-89FF-5C1777A13931Q64896551-B65F8532-6445-4E83-9CB5-9DC98ED249A8Q64901703-B507E045-6E02-4529-9112-E1B948C090FDQ90304890-F88EB9FB-85FB-4D47-B456-66CB376ED69DQ91058922-45DECC0D-D825-4CF0-8494-B0C37CBCC01BQ92110038-870EEF1F-EE52-4414-A7CF-49E81516D3CAQ92162139-8D0D5E2A-CCC8-4559-9A47-36C5E22D337BQ92249235-BF874649-C470-4F43-B9BE-769AB2E26011
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9039-5258
@en
name
S. Yousuf Zafar
@ast
S. Yousuf Zafar
@en
S. Yousuf Zafar
@es
S. Yousuf Zafar
@nl
type
label
S. Yousuf Zafar
@ast
S. Yousuf Zafar
@en
S. Yousuf Zafar
@es
S. Yousuf Zafar
@nl
prefLabel
S. Yousuf Zafar
@ast
S. Yousuf Zafar
@en
S. Yousuf Zafar
@es
S. Yousuf Zafar
@nl
P106
P108
P1153
24492583800
P31
P496
0000-0002-9039-5258